FDA Approves the First Drug for Neurotrophic Keratitis

FDA Approves the First Drug for Neurotrophic Keratitis

Source: 
CP Wire
snippet: 

The U.S. Food and Drug Administration announced on 8/22/18 that it has approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye). Qxervate was developed by the Italian pharmaceutical company Dompé farmaceutici SpA.